Menu

New Data Attempt to Resolve Protein Dispute

The latest analysis on GDF11, a proposed antiaging protein, blames discrepancies in the literature on misreported doses and misinterpretation.

Oct 22, 2015
Kerry Grens

WIKIPEDIA, DR. S. GIROD, ANTON BECKERA protein called growth differentiation factor 11 (GDF11) has been at the center of a tug of war: some scientists have provided evidence that it declines with age, and that returning GDF11 to youthful levels can fix a heart problem in mice. Yet others have found no such relationship, and one group published evidence this year that GDF11 actually increases with age.

To figure out why there have been discrepancies in the data, Richard Lee of Harvard Medical School and his colleagues—the team that found GDF11 dropped with age—scrutinized a conflicting study and found the likely explanation to be a case of mistaken identity. Rather than measuring levels of GDF11, Lee’s group found, the other researchers were likely measuring immunoglobulin light chain. “It’s a misinterpretation,” Lee told The Scientist.

Novartis Research Institutes, which led the study that found GDF11 levels rising with age, did not respond to requests for comment. Lee told The Scientist he had pointed out the error to the Novartis team over the summer, but has not heard back.

This week (October 21), the Harvard group showed in Circulation Research that an antibody against GDF11 used in Western blot analyses also recognizes immunoglobulin, and that eliminating immunoglobulin from the assay wipes out the band. Mass spectra of the band also indicated that the signal came from immunoglobulin.

Steven Houser of Temple University School of Medicine, who was not involved in either study, says Lee’s data in support of a misinterpretation by Novartis are strong. “It looks like the Novartis group misidentified a band as GDF11,” he said. But he added that questions about GDF11’s effects on the heart are still unresolved.

Last month, Houser’s team reported evidence conflicting with Lee’s data on cardiac hypertrophy, or thickening of the heart muscle. Lee’s team had found that giving older mice a boost in GDF11 levels fixed their cardiac hypertrophy. Houser’s group, on the other hand, found no effect.

According to the Lee group’s latest paper, the difference might be due to variability in the concentration of GDF11. Originally, Lee’s team—as subsequently replicated by Houser’s—used a concentration of 0.1 mg/kg, but it turns out that the manufacturer had sent the Lee group variable concentrations. Now, the Harvard researchers have reported, a concentration of 0.5 mg/kg is the effective dose.

“They think the dose was higher than they realized. That’s troubling, to be honest,” Hauser told The Scientist. “If they knew the dose to be reported was not the right dose, there are ways to inform the field.”

Lee agreed there is still much to be learned about GDF11, and this latest study does not put questions about its activity to bed. “I think a lot of this is, early on in the field the reagents aren’t perfect, the assays aren’t perfect, so people get results that look like they’re opposing each other. . . . We need better assays, we need more science, we really just need to do more work.”

T. Poggioli et al., “Circulating growth fifferentiation factor 11/8 levels decline with age,” Circulation Research, doi:10.1161/CIRCRESAHA.115.307521, 2015.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.